| Name | Title | Contact Details |
|---|
Eidos Therapeutics, a subsidiary of BridgeBio Pharma, is developing AG10 as a targeted therapeutic for transthyretin amyloidosis.
A2 is dedicated to pushing the boundaries of science to transform medicine and turn the tide on cancer. We are focused on the next frontier in cell therapy: solid tumors.
STIMIT`s proprietary technology enables extended local delivery of cancer immunotherapy in the context of tumor resection, the standard of care for most patients with solid tumors. Concentrating and retaining the action of potent immunomodulators locally dramatically improves the efficacy and safety of these compounds relative to administration in solution, whether via intravenous or even intratumoral injection.
MeMed is a host response, med-tech & bioconvergence company, offering innovative diagnostic host response tests that address complex clinical dilemmas & improve patient outcomes.
Cajal Neuroscience is a drug discovery company focused on neurodegenerative disease.